These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8241372)

  • 1. Optimization of multistage testing times and critical values in clinical trials.
    Brittain EH; Bailey KR
    Biometrics; 1993 Sep; 49(3):763-72. PubMed ID: 8241372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing for the existence of a desirable dose combination.
    Hung HM; Chi GY; Lipicky RJ
    Biometrics; 1993 Mar; 49(1):85-94. PubMed ID: 8513112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of experiments with adaptive interim analyses.
    Bauer P; Köhne K
    Biometrics; 1994 Dec; 50(4):1029-41. PubMed ID: 7786985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Designed extension of studies based on conditional power.
    Proschan MA; Hunsberger SA
    Biometrics; 1995 Dec; 51(4):1315-24. PubMed ID: 8589224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.
    Jennison C; Turnbull BW
    Biometrics; 1993 Sep; 49(3):741-52. PubMed ID: 8241370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design considerations in crossover trials with a single interim analysis and serial patient entry.
    Cook RJ; Willan AR
    Biometrics; 1996 Jun; 52(2):732-9. PubMed ID: 8672709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An optimal design for screening trials.
    Wang YG; Leung DH
    Biometrics; 1998 Mar; 54(1):243-50. PubMed ID: 9544519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Bayesian design for patient selection in a clinical study.
    Buzoianu M; Kadane JB
    Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-stage design for choosing among several experimental treatments and a control in clinical trials.
    Thall PF; Simon R; Ellenberg SS
    Biometrics; 1989 Jun; 45(2):537-47. PubMed ID: 2765637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal sample size for a series of pilot trials of new agents.
    Yao TJ; Begg CB; Livingston PO
    Biometrics; 1996 Sep; 52(3):992-1001. PubMed ID: 8805764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-stage clinical trial stopping rules.
    Elashoff JD; Reedy TJ
    Biometrics; 1984 Sep; 40(3):791-5. PubMed ID: 6518247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive designs with correlated test statistics.
    Götte H; Hommel G; Faldum A
    Stat Med; 2009 May; 28(10):1429-44. PubMed ID: 19226563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variance estimation in clinical studies with interim sample size re-estimation.
    Miller F
    Biometrics; 2005 Jun; 61(2):355-61. PubMed ID: 16011681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A note on P-values under group sequential testing and nonproportional hazards.
    Gillen DL; Emerson SS
    Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comment on interim analyses in crossover trials.
    Grieve AP; Senn S
    Biometrics; 1996 Dec; 52(4):1515-20. PubMed ID: 9019232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A group sequential procedure for all-pairwise comparisons of k treatments based on the range statistic.
    Liu W
    Biometrics; 1995 Sep; 51(3):946-55. PubMed ID: 7548710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal two-stage design for a series of pilot trials of new agents.
    Yao TJ; Venkatraman ES
    Biometrics; 1998 Sep; 54(3):1183-9. PubMed ID: 9750258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global measures of local influence for proportional hazards regression models.
    Barlow WE
    Biometrics; 1997 Sep; 53(3):1157-62. PubMed ID: 9290233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.